Foundational Discovery · 2006
Induced Pluripotent Stem Cells (iPSCs)
The decade before 2006 had produced a prolonged political and ethical impasse over human embryonic stem cell research. In the United States, federal funding for work on newly derived cell lines was restricted after August 2001, and researchers in many countries faced legal uncertainty or outright prohibition. The scientific appeal of pluripotent stem cells was clear: they could theoretically differentiate into any tissue type, offering tools for disease modeling and, eventually, regenerative therapies. The central obstacle was that creating them required embryos, which made the field politically volatile.
Shinya Yamanaka, working at Kyoto University's Institute for Frontier Medical Sciences, approached the problem differently. If embryonic stem cells maintained their pluripotency through the activity of specific transcription factors, he reasoned, perhaps reactivating those factors in a mature somatic cell could reverse its differentiated state. His laboratory screened a set of candidate genes and arrived at four: Oct3/4, Sox2, c-Myc, and Klf4. His co-investigator Kazutoshi Takahashi performed the key experiments, introducing all four factors via retroviral vectors into adult mouse fibroblasts. The August 2006 Cell paper reported that the resulting cells, which Yamanaka named induced pluripotent stem cells, closely resembled embryonic stem cells in morphology, gene expression profiles, and capacity to differentiate into the three primary germ layers.
The initial mouse result was striking but needed rapid replication in human cells to be clinically meaningful. Within a year, two papers appeared nearly simultaneously: Yamanaka's group reported human iPSCs using the same four factors in November 2007, and James Thomson's laboratory at the University of Wisconsin published human iPSC generation using a different factor combination (Oct4, Sox2, Nanog, and Lin28) days later. Both papers appeared in the same week, establishing independent confirmation of the approach.
For the research community, iPSCs addressed the ethical obstacle without resolving all scientific ones. Early cell lines carried retroviral integrations that raised safety concerns for any therapeutic application, and c-Myc was a known oncogene. Subsequent work developed non-integrating reprogramming methods using episomal vectors, mRNA transfection, and small molecules, reducing but not eliminating the technical hurdles to clinical use. Disease modeling became the field's most immediate practical application, allowing researchers to generate cardiomyocytes, neurons, and hepatocytes from patients with long QT syndrome, ALS, and Parkinson's disease and study pathophysiology in cells carrying the patient's own genetic background.
Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon of Cambridge, whose nuclear transfer experiments in frogs during the 1960s had first demonstrated that differentiated cells retain a complete genome and can be reprogrammed under the right conditions. The Nobel Committee recognized the two discoveries as complementary, spanning half a century. As of the mid-2020s, iPSC-derived cell therapies are in early clinical trials for conditions including Parkinson's disease, macular degeneration, and heart failure, though no iPSC-based product has yet received broad regulatory approval.
Key People
- Shinya Yamanaka — Kyoto University; senior author, iPSC discovery; 2012 Nobel laureate
- Kazutoshi Takahashi — First author; performed the key mouse reprogramming experiments
- James Thomson — University of Wisconsin; independently achieved human iPSC reprogramming in 2007
- John Gurdon — Cambridge; nuclear transfer pioneer; shared 2012 Nobel with Yamanaka
Cell. 2006;126(4):663-676.
Related landmarks
- 1973 · Lauterbur's NMR imaging (zeugmatography), origin of MRI (Foundational Discovery)
- 1971 · First clinical CT scanner (EMI head scanner) (Foundational Discovery)
- 1955 · Sanger's Sequencing of Insulin (Foundational Discovery)
- 1932 · Identification of vitamin C as the antiscorbutic factor (Foundational Discovery)